Literature DB >> 29282751

Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy.

B H L Harris1,2, J L Walsh3, R Neciunaite4, P Manders1, A Cooper1,5,6, P De Souza1,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29282751     DOI： 10.1111/ced.13302

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  2 in total

Review 1.  Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma.

Authors:  Marc-Antoine Valantin; Léna Royston; Maxime Hentzien; Aude Jary; Alain Makinson; Marianne Veyri; Sylvie Ronot-Bregigeon; Stéphane Isnard; Romain Palich; Jean-Pierre Routy
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

2.  A Series of Patients with Kaposi Sarcoma (Mediterranean/Classical Type): Case Presentations and Short Update on Pathogenesis and Treatment.

Authors:  Ivanka Temelkova; Michael Tronnier; Ivan Terziev; Uwe Wollina; Ilia Lozev; Mohamad Goldust; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2018-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.